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PKA Phosphorylation Dissociates FKBP12.6 from the
Calcium Release Channel (Ryanodine Receptor):
Defective Regulation in Failing Hearts
channels, resulting in the appearance of subconduc-
tance states and increased Po due to an increased sensi-
tivity to Ca21-dependent activation (Brillantes et al.,
1994; Kaftan et al., 1996). In addition, dissociation of
FKBP12 from RyR channels inhibits coupled gating, re-
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FKBPs are cis-trans peptidyl-prolyl isomerases that
are widely expressed and subserve a variety of cellular
Summary functions (Marks, 1996). FKBP12s are tightly bound to
and regulate the function of the skeletal (RyR1) (Jayara-
The ryanodine receptor (RyR)/calcium release channel man et al., 1992; Brillantes et al., 1994) and cardiac
on the sarcoplasmic reticulum (SR) is the major source (RyR2) (Kaftan et al., 1996) muscle Ca21 release chan-
of calcium (Ca21) required for cardiac muscle excita- nels, as well as related intracellular Ca21 release chan-
tion-contraction (EC) coupling. The channel is a tetra- nels: the type 1 inositol 1,4,5-trisphosphate receptor
mer comprised of four type 2 RyR polypeptides (RyR2) (IP3R1) (Cameron et al., 1997) and the type I TGFb recep-
and four FK506 binding proteins (FKBP12.6). We show tor (TbRI) (Chen et al., 1997).
that protein kinase A (PKA) phosphorylation of RyR2 In the present study, we demonstrate that PKA phos-
dissociates FKBP12.6 and regulates the channel open phorylation regulates the binding of FKBP12.6 to the
probability (Po). Using cosedimentation and coimmu- channel both in vitro and in vivo. PKA phosphorylation
noprecipitation we have defined a macromolecular of the cardiac SR Ca21 release channel/RyR2 dissoci-
complex comprised of RyR2, FKBP12.6, PKA, the pro- ates the regulatory subunit FKBP12.6 from the channel,
tein phosphatases PP1 and PP2A, and an anchoring resulting in altered channel function manifested as an
protein, mAKAP. In failing human hearts, RyR2 is PKA increased Po, increased sensitivity to Ca21-induced acti-
hyperphosphorylated, resulting in defective channel vation, and destabilization of the channel resulting in
function due to increased sensitivity to Ca21-induced subconductance states. RyR2 PKA phosphorylation is
activation. physiologically regulated in vivo. Channels from failing
hearts were PKA hyperphosphorylated. RyR2 channels
from failing hearts exhibited decreased binding of the
Introduction FKBP12.6 regulatory subunit, resulting in the same se-
vere defects in single channel properties observed in in
Calcium (Ca21) release channels (ryanodine receptor) on vitro PKA hyperphosphorylated channels. We show that
the sarcoplasmic reticulum (SR) of striated muscles are the RyR2 channel comprises a macromolecular complex
required for EC coupling. In cardiac muscle, the type 2 that includes FKBP12.6, PKA, RII, the phosphatases PP1
ryanodine receptor (RyR2) is a tetramer comprised of and PP2A, and an anchoring protein, mAKAP. Taken
four 565,000 dalton RyR2 polypeptides and four 12,000 together, these data demonstrate that local regulation
dalton FK-506 binding proteins (FKBP12.6). FKBP12s of the RyR2 channel via PKA phosphorylation is a potent
are regulatory subunits that stabilize RyR channel func- mechanism for modulating SR Ca21 release. Dysregula-
tion (Brillantes et al., 1994) and facilitate coupled gating tion of this control mechanism occurs in failing hearts
between neighboring RyR channels (Marx et al., 1998) and can explain the observed defects in EC coupling
which are packed into dense arrays in specialized re- that contribute to cardiac dysfunction.
gions of the SR that release intracellular stores of Ca21
that trigger muscle contraction.
ResultsRyRs are ligand-activated channels and Ca21 is the
important physiological ligand that activates the chan-
PKA Phosphorylates RyR2nels in cardiac muscle during EC coupling. The Ca21
The 565,000 dalton RyR2 polypeptide was PKA phos-dependence of RyR channel activity is biphasic such
phorylated in in vitro kinasing reactions (Figure 1A). Tothat low cytosolic [Ca21] (mM) activates the channels
confirm the identity of the PKA phosphorylated highand high cystolic [Ca21] (mM) inactivates the channels
molecular weight protein as RyR2, the phosphorylated(Bezprozvanny et al., 1991). One FKBP12 molecule is
band was immunoblotted with anti-RyR antibody. Thebound to each RyR subunit, and dissociation of FKBP12
specificity of the phosphorylation was demonstrated us-significantly alters the biophysical properties of the
ing a PKA inhibitor (PKI) (Figure 1A). Addition of phos-
phorylation buffer, including cAMP without exogenous
PKA, also resulted in phosphorylation of RyR2 that was§ To whom correspondence should be addressed (e-mail: arm42@
inhibited by PKI, indicating that endogenous PKA wascolumbia.edu).
k These authors contributed equally to this work. associated with RyR2 (Figure 1A). The stoichiometry of
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Figure 1. PKA Phosphorylation of RyR2, a
Macromolecular Signaling Complex
(A) Immunoprecipitated RyR2 was phosphor-
ylated with PKA (5 units), or cAMP (10 mM),
and PKA inhibitor PKI5±24 (500 nM) inhibited
the phosphorylation. Equivalent amounts of
RyR2 protein were used in each reaction as
shown by immunoblotting.
(B) RyR2 channels were isolated using [3H]ry-
anodine by sucrose density gradient centrifu-
gation as described (Brillantes et al., 1994).
[3H]ryanodine binding (open squares) and to-
tal protein (filled circles) were plotted. Individ-
ual RyR2 channels sediment at 30S (arrow),
and 2 or more physically attached RyR2
channels sediment in higher sucrose frac-
tions as previously reported for RyR1 chan-
nels (Marx et al., 1998).
(C) Immunoblotting gradient fractions with
specific antibodies showed that FKBP12.6,
PKA catalytic subunit, PKA regulatory sub-
unit (RII), PP2A, PP1, and mAKAP, but not
CnA were detected in all fractions containing
RyR2.
(D) RyR2 binding to microcystin-Sepharose
beads was competed using free microcystin-
LR. Samples were pelleted and analyzed by
SDS-PAGE and immunoblotting with anti-
RyR antibody.
(E) Components of the RyR2 complex
(FKBP12.6, PKA, RII, PP2A, PP1, and mAKAP)
were coimmunoprecipitated from cardiac
SR (200 mg). The RyR2 complex was sedi-
mented using microcystin-Sepharose, the
complex was competed off with free micro-
cystin-LR followed by immunoprecipitation
with anti-RyR antibody (aRyR) and immu-
noblotting. Positive controls (1Cont.) were
recombinant or purified proteins as indicated,
negative controls (2Cont.) were blocking
peptides or IgG. In all cases data shown are
representative of more than three similar ex-
periments.
PKA phosphorylation was determined by immunopre- immunoblotted with either anti-RyR antibody or with anti-
bodies that recognize FKBP12.6, the catalytic subunitcipitating RyR2 from cardiac muscle SR, fully dephos-
phorylating the RyR2 protein with alkaline phosphatase, of PKA, the PKA regulatory subunit (RII), PP2A, PP1,
mAKAP, or CnA, (Figure 1C) all of which (with the excep-and then phosphorylating it with PKA and [g32P]ATP.
The stoichiometry of PKA phosphorylation was 3.8 6 0.1 tion of CnA) were detected in all fractions containing
RyR2. These data are consistent with a high molecularmoles of phosphate per mole of channel (each channel
comprises four RyR2 subunits), or one per RyR2 subunit, weight complex comprised of RyR2, FKBP12.6, PKA,
RII, PP1, PP2A, and mAKAP.indicating that each RyR2 protein is PKA phosphory-
lated on a single amino acid residue. The phosphatase inhibitor microcystin binds to PP1
and PP2A. RyR2 was sedimented by binding to micro-
cystin-Sepharose beads and the specificity of this inter-RyR2 Macromolecular Complex Includes FKBP12.6,
action was demonstrated by competing off RyR2 usingPKA, PP1, PP2A, and mAKAP
free microcystin-LR (Figure 1D). Coimmunoprecipi-RyR2 was isolated by sucrose density gradient centrifu-
tations were performed showing that FKBP12.6, PKA,gation using [3H]ryanodine (Figure 1B) as described
RII, PP2A, PP1, and mAKAP all coimmunoprecipitated(Marx et al., 1998). Individual tetrameric RyR2 channels
with RyR2, indicating physical association of these pro-sediment as 30S complexes and multiple channels (two
teins with the SR Ca21 release channel (Figure 1E). Theor more) sediment as denser complexes (Marx et al.,
existence of a macromolecular complex was shown in-1998). The muscle A kinase anchoring protein (mAKAP)
dependently by first sedimenting the complex with mi-that binds PKA and targets it to substrates has been
crocystin-Sepharose beads, followed by competing thelocalized to cardiac SR (Yang et al., 1998; Kapiloff et
complex off from the beads with free microcystin-LR,al., 1999). The major protein phosphatases in cardiac
and then immunoprecipitating each of the componentsmuscle are protein phosphatase 2A (PP2A), protein
of the complex (Figure 1E, last three lanes). Taken to-phosphatase 1 (PP1) (MacDougall et al., 1991), and cal-
cineurin (CnA). Fractions from the sucrose gradient were gether, these data show that FKBP12.6, PKA, RII, PP1,
PKA Phosphorylation of RyR2
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PP2A, and mAKAP comprise a macromolecular complex and the post-LVAD sample comes from hearts with im-
proved function. PKA phosphorylation of RyR2 was sig-with RyR2.
nificantly increased in pre-LVAD heart samples com-
pared to samples from nonfailing hearts and returnedPKA Hyperphosphorylation of RyR2 in Failing
to normal levels following LVAD treatment (Figures 2AHeart Muscle
and 2B). Taken together, these data show: (1) PKA phos-Increased sympathetic activity is an important physio-
phorylation of RyR2 is regulated physiologically in vivo,logic response to stress, resulting in activation of the
(2) heart failure is associated with increased PKA phos-adrenergic signaling pathway that generates increased
phorylation of RyR2, and (3) the PKA phosphorylationcAMP levels and activates PKA. In failing hearts (regard-
of RyR2 returns to normal levels when the cardiac func-less of the etiology of the damage to the heart), circulat-
tion is improved by an LVAD.ing catecholamine levels are markedly increased. We
Many patients with end-stage heart failure are treatedexamined specific PKA phosphorylation of RyR2 in nor-
with b-adrenergic agonists (e.g., dobutamine) prior tomal and failing hearts using both back-phosphorylation
cardiac transplantation, while some patients are admit-with [g32P]ATP and anti-phosphoserine immunoblots
ted directly from home when a donor heart becomes(Figures 2A and 2B).
available (and therefore are not receiving b-adrenergicStrikingly, PKA phosphorylation of RyR2 was signifi-
agonists). PKA phosphorylation of RyR2 was signifi-cantly elevated in failing hearts from humans and from
cantly elevated in the hearts from patients not on b-adren-animal models (dogs with pacing-induced heart failure)
ergic agonists compared to normals (Figures 2A andcompared to nonfailing hearts (Figures 2A and 2B). PKA
2B). PKA phosphorylation of RyR2 was significantly fur-phosphorylation of RyR2 channels from failing hearts
ther increased in hearts from those patients treated withwas increased z4-fold compared to RyR2 channels
b-adrenergic agonists prior to cardiac transplantationfrom nonfailing hearts. The stoichiometry of PKA back-
(Figures 2A and 2B). These data indicate that exogenousphosphorylation of RyR2 channels isolated from failing
administration of b-adrenergic agonists to patients withhearts was 0.7 6 0.3 moles of phosphate transferred
heart failure can further increase the PKA phosphoryla-per mole of channel (n 5 8) compared to 3.1 6 0.1 moles
tion of RyR2 in the heart.of phosphate transferred per mole of channel from nor-
To determine whether the increased PKA phosphory-mal nonfailing hearts (n 5 6, p , 0.0001). These data
lation of RyR2 observed in failing hearts was explainedsuggest that in failing hearts, approximately three of
by an increase in PKA activity or by a decrease in phos-the four PKA sites on the tetrameric RyR2 channel are
phatase activity, the amounts of PP1 and PP2A physi-phosphorylated in vivo, whereas only one site is phos-
cally associated with RyR2 in failing hearts were com-phorylated in vivo on RyR2 isolated from normal nonfail-
pared to those in normal hearts from humans and dogsing hearts.
(Figures 2C and 2D). There was a significant decreaseThis increase in PKA phosphorylation of RyR2 was
in the levels of PP1 and PP2A that coimmunoprecipi-not due to an increase in the levels of PKA protein asso-
tated with RyR2 from failing hearts (Figures 2C and 2D).ciated with RyR2 in failing hearts as determined by coim-
The decrease in the amount of PP1 (but not of PP2A)munoprecipitation of PKA with RyR2 (Figure 2A). PKA
associated with RyR2 was restored to normal by LVADback-phosphorylation was performed using immuno-
treatment (Figures 2C and 2D). These data suggest that,precipitated RyR2 to ensure that the phosphorylation
at least in part, the PKA hyperphosphorylation of RyR2signal which was measured represented specifically
is due to a decrease in phosphatase bound to the RyR2RyR2 PKA phosphorylation. We have previously re-
channel macromolecular complex.ported that the levels of RyR2 are decreased in failing
hearts (Go et al., 1995). PKA phosphorylation of RyR2
was normalized to the amount of immunoprecipitated
Mapping Signaling Complex Binding Sites on RyR2RyR2 protein to enable valid comparisons of the amount
The FKBP12.6 binding site on RyR2 was identified usingof PKA phosphorylation per RyR2 molecule from normal
a yeast two-hybrid protein interaction screen in whichand failing hearts (Figures 2A and 2B). Moreover, identi-
yeast were transformed with vectors containing eithercal results were obtained when immunoprecipitated
fragments of RyR2 or the full-length FKBP12.6 fusedRyR2 was immunoblotted with an anti-phosphoserine
to the Gal4 activation domain or DNA binding domain.antibody (e.g., see Figure 2B, inset) confirming that the
One RyR2 fragment corresponding to amino acid resi-RyR2 channels from failing hearts were PKA hyper-
dues 2361±2496 resulted in a positive interaction withphosphorylated compared to channels from nonfailing
FKBP12.6 (Figure 3A). Rapamycin inhibited the interac-hearts.
tion between FKBP12.6 and RyR2 (Figure 3A) in a con-Left ventricular assist devices (LVADs) are used as a
centration-dependent manner in rapamycin-resistantbridge to transplantation when donor hearts are not
yeast (Lorenz and Heitman, 1995), indicating that theavailable. Studies have shown that the hemodynamic
interaction between FKBP12.6 and RyR2 was specific.unloading of the left ventricle provided by LVADs results
The hydrophobic FKBP12.6 binding site comprised ofin a significant improvement in cardiac contractile func-
isoleucine 2427 and proline 2428 is homologous to thetion when the device is implanted in failing hearts (Levin
FKBP12 binding site in RyR1, IP3R1 (Cameron et al.,et al., 1995). At the time of LVAD insertion, a tissue core
1997), and TbRI (Figure 3A). Using GST-RyR2 fusionis removed from the patient's left ventricle and this can
proteins in pull-down assays with cardiac SR, bindingthen be compared to tissue from the explanted heart
domains for PP1 (residues 513±808) and PP2A (residuesthat becomes available at the time of transplantation.
Thus, the pre-LVAD sample comes from failing hearts 1451±1768) were mapped (Figure 3B). Interestingly, both
Cell
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Figure 2. RyR2 PKA Phosphorylation during Heart Failure
(A) PKA back-phosphorylation of RyR2 protein immunoprecipitated from the indicated tissues is shown in the top row; the middle row shows
the amount of RyR2 immunoprecipitated in each reaction; and the bottom row shows the amount of PKA coimmunoprecipitated with RyR2
from each sample. Normal, nonfailing human heart; ICM, end-stage failing human heart with ischemic cardiomyopathy; IDCM, end-stage
failing human heart with idiopathic dilated cardiomyopathy; IDCM(2Dba), samples from patients not treated with a b-adrenergic agonist, Dba
(dobutamine); Pre-LVAD, left ventricular sample taken from a human heart with end-stage failure during insertion of an LVAD; Post-LVAD,
sample from the same human heart after LVAD treatment; PKI, representative negative control showing that PKA phosphorylation was inhibited
by PKI.
(B) Quantitation of RyR2 back-phosphorylation studies shown in (A). The inset shows PKA hyperphosphorylation of RyR2 confirmed by anti-
phosphoserine immunoblotting: (1) top row, RyR2 immunoblot (top lanes); (2) bottom row, anti-phosphoserine immunoblotting of the same
samples. Lane 1, normal human heart; lane 2, failing human (ICM) heart. For each condition, a minimum of three experiments using tissue
from three different hearts were performed; error bars represent standard deviation of the mean.
(C) PP1 and PP2A coimmunoprecipitated with RyR2 from normal and failing hearts. Following immunoprecipitation with anti-RyR antibody,
immunoprecipitates were size-fractionated and immunoblotted with: anti-RyR2 (top panel), anti-PP1 (middle panel), or anti-PP2A (bottom
panel) antibodies. Data shown are representative of three similar experiments.
(D) The amount of PP1 and PP2A coimmunoprecipitating with RyR2 was determined by densitometric quantitation of the immunoblots and
normalized for the amount of RyR2 coimmunoprecipitated. Less PP1 and PP2A was associated with RyR2 in all of the heart failure samples.
Data shown are representative of three similar experiments.
PKA Phosphorylation of RyR2
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Figure 3. Mapping Signaling Complex Bind-
ing Sites on RyR2
(A) The FKBP12.6 binding site in RyR2 was
identified using a yeast two-hybrid interac-
tion screen. Left bar graph shows b-galacto-
sidase activity for yeast transformed with: (1)
FKBP12.6/activation domain fusion protein
alone, (2) RyR2 (residues 2361±2496)/DNA
binding domain alone, and (3) both. Inter-
action between FKBP12.6 and an RyR2
fragment (residues 2361±2496) activates
Gal-4 transcription resulting in increased
b-galactosidase activity. The right bar graph
shows normalized b-galactosidase activity for
rapamycin-resistant yeast transformed with
FKBP12.6 and the RyR2 fragment treated
with the indicated concentrations of rapa-
mycin which competes FKBP12.6 off from
RyR2. The FKBP12/12.6 binding site is de-
fined by isoleucine 2427 and proline 2428
(arrow). Sequences of FKBP12 binding sites
in RyR1, IP3R1, IP3R2, and TbRI are shown
in the box.
(B) GST-RyR2 fusion proteins bound to Seph-
arose beads were incubated with cardiac SR
(200 mg), pelleted, size fractionated by SDS-
PAGE, and immunoblotted with the indicated
antibodies. Lane 1, positive control (recombi-
nant proteins); lane 2, Sepharose beads (neg-
ative control); lane 3, GST (negative control);
lane 4, GST-RyR2±1±334 (amino acid resi-
dues 1±334); lane 5, GST-RyR2±513±808; lane
6, GST-RyR2±1027±1304; lane 7, GST-RyR2±
1251±1500; lane 8, GST-RyR2±1451±1768.
(C) Immunohistochemistry showing colocal-
ization of mAKAP and RyR2 to cardiac SR in
normal and failing human hearts. Bars: long,
1.5 mm; short, 5 mm.
(D) In vitro kinasing reactions using GST-
RyR2 fusion proteins containing the wild-
type (wt) and mutant (S2809A) PKA site.
PKA phosphorylation was performed with
[g32P]ATP followed by size-fractionation on
SDS-PAGE and autoradiography.
contain leucine/isoleucine zippers. Immunohistochem- reduction, n 5 4, p , 0.005) and in dogs with pacing-
induced heart failure (50% 6 8% reduction, n 5 3, p ,istry showed that mAKAP is present in the cardiac SR,
the same cellular location as RyR2, in both normal and 0.005) (Figure 4B). Total FKBP12.6 levels in homoge-
nates from normal and failing hearts were the same (datafailing human hearts (Figure 3C). Wild-type and mutant
GST-RyR2 fusion proteins were used to determine the not shown). These data show that PKA phosphorylation
of RyR2 provides a mechanism for the physiologic andsite of PKA phosphorylation (serine 2809) (Figure 3D).
pathophysiologic regulation of FKBP12.6 binding to
RyR2.PKA Phosphorylation of RyR2 Inhibits
FKBP12.6 Binding
PKA phosphorylation of immunoprecipitated RyR2 (there RyR2 PKA Phosphorylation Increases Po
and Induces Subconductance Stateswas no PKA phosphorylation of FKBP12.6) resulted in
a decrease (z90 6 9% reduction, n 5 8, p , 0.001) in We have previously shown that dissociation of FKBP12/
12.6 from RyR1 or RyR2 increases the channel Po bythe amount of FKBP12.6 coimmunoprecipitating with
RyR2 (Figure 4A). No dissociation of FKBP12.6 from shifting the Ca21 dependence for activation to the left
(Brillantes et al., 1994; Kaftan et al., 1996). A secondRyR2 was observed in the following negative controls:
(1) including PKI in the reaction, (2) boiling the PKA, or effect of dissociation of FKBP12/12.6 from the channels
is to induce subconductance states consistent with a(3) omitting ATP. Neither Ca21 calmodulin kinase (CaM-
KII) nor protein kinase C (PKC) caused the dissocia- destabilization of the tetrameric channel structure (Bril-
lantes et al., 1994). PKA phosphorylation of RyR2 intion of FKBP12.6 from RyR2, indicating that the PKA
phosphorylation-induced dissociation of FKBP12.6 from planar lipid bilayers resulted in a significant increase in
Po from 0.10 6 0.03 to 0.35 6 0.06 (n 5 4/4, p , 0.001)RyR2 is specific (Figure 4A). Furthermore, less FKBP12.6
coimmunoprecipitated with RyR2 from failing hearts (e.g., Figure 5A). PKA phosphorylation of RyR2 also in-
duced subconductance states (n 5 4) (e.g., Figure 5B)compared to normal hearts in both humans (65% 6 11%
Cell
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data suggest that PKA phosphorylation activates RyR2
by dissociating FKBP12.6 from the channel resulting in
increased sensitivity to Ca21-induced activation.
Heart Failure and PKA Hyperphosphorylation
Produce the Same RyR2 Defects
Single channel recordings of RyR2 channels from human
(n 5 21, 13 channels from 3 patients with heart failure
including 3 channels from pre-LVAD treatment heart
samples, 4 channels from nonfailing hearts, and 4 chan-
nels from hearts post-LVAD treatment) and canine (n 5
27, 14 channels from 2 dogs with pacing-induced heart
failure and 13 channels from nonfailing hearts) hearts
revealed that the RyR2 channels from failing hearts ex-
hibited the same alterations in single channel properties
(Figures 6A and 6B) as the PKA phosphorylated chan-
nels (Figure 5B). RyR2 channels from failing hearts ex-
hibited an increased Po at low cis (cytosolic) [Ca21] (50
nM, 0.24 6 0.21 versus 0.002 6 0.001, n 5 27 failing
hearts, n 5 21 nonfailing and post-LVAD hearts, p ,
0.0001). At 50 nM cis [Ca21], 70% of the RyR2 channels
from failing hearts (19/27) exhibited increased Po (Po .
0) compared with 9.5% (2/21) channels from nonfailing
hearts. Moreover, there were two types of behavior ex-
hibited by RyR2 channels that were active at 50 nM
cis [Ca21]. 56% of RyR2 channels from failing hearts
exhibited low levels of activity (n 5 15/27, Po < 0.03),
whereas channels from normal hearts are almost always
completely inactive at 50 nM cis [Ca21] (Figure 6B). Strik-
ingly, 15% of the RyR2 channels from failing hearts (n 5
4/27) exhibited a second type of behavior that was never
observed in channels from normal hearts: a long-lasting
Figure 4. PKA Phosphorylation of RyR2 Inhibits FKBP12.6 Binding
subconductance state at 50 nM cis [Ca21] with Po <(A) FKBP12.6 was coimmunoprecipitated from cardiac SR using an
1.0 (Figure 6B) similar to those observed following PKAanti-RyR antibody followed by immunoblotting with either anti-RyR
phosphorylation of RyR2 channels in the bilayer (e.g.,(top panel) or anti-FKBP (bottom panel) antibodies. The indicated
see Figure 5B). These subconductance states had mark-immunoprecipitates were phosphorylated with PKA prior to size-
fractionation by SDS-PAGE. Coimmunoprecipitation of FKBP12.6 edly increased open times (to 5 802.1 6 66.7 ms) com-
with RyR2 was significantly reduced in the PKA phosphorylated pared to the RyR2 channels from nonfailing hearts (to 5
samples but not in CaMKII or PKC phosphorylated RyR2 samples. 2.2 6 0.7 ms) (e.g., see Figure 6B). RyR2 channels that
(B) Quantitation of FKBP12.6 coimmunoprecipitating with RyR2 from are active at 50 nM cytosolic [Ca21] would be expected
the indicated samples. Normal human heart; pre-LVAD, left ventricu-
to be open throughout the cardiac cycle (in systole andlar sample taken from a human heart with end-stage failure during
diastole).insertion of a left ventricular assist device; Post-LVAD, sample from
In 52% of RyR2 channels from failing hearts, subcon-the same human heart after LVAD treatment; IDCM, end-stage failing
human heart with idiopathic dilated cardiomyopathy; normal nonfail- ductance states were observed (n 5 14/27) that were
ing canine heart; canine rapid pacing-induced heart failure model. present in less than 5% of channels from normal hearts
Inset shows representative coimmunoprecipitations of RyR2 and (n 5 1/21, p , 0.001) (e.g., see Figure 6A). The subcon-
FKBP12.6 using an anti-RyR antibody: lane 1, normal human heart; ductance states are similar to those observed when
lane 2, pre-LVAD; lane 3, post-LVAD; lane 4, human IDCM; lane 5,
RyR1 channels are expressed without FKBP12 (Bril-normal canine heart; lane 6, failing canine heart. There was signifi-
lantes et al., 1994) or when FKBP12.6 is dissociatedcantly less FKBP12.6 coimmunoprecipitated with RyR2 in each of
from native RyR2 channels (Kaftan et al., 1996) and inthe failing hearts compared to normals. Data shown are representa-
tive of three or more similar experiments. FKBP12.6 amounts were PKA phosphorylated channels (Figure 5A). As noted
quantified using densitometry. above, channels from failing hearts also exhibited in-
creased PKA phosphorylation (Figures 2A and 2B) and
reduced FKBP12.6 binding (Figure 4B). These data sug-
similar to those seen after dissociation of FKBP from gest that increased PKA phosphorylation of RyR2 in
the RyR channels (Brillantes et al., 1994; Kaftan et al., failing hearts results in dissociation of FKBP12.6, which
1996; Marx et al., 1998). PKA phosphorylation of RyR2 causes defects in the single channel properties charac-
channels did not alter the mean open time (to) of the full terized by subconductance states and increased Po con-
conductance state (control channels to 5 2.1 6 0.8 ms sistent with destabilized channels and altered Ca21 sen-
vs. 2.6 6 0.6 ms following PKA, n 5 4, p 5 NS). However, sitivity (Brillantes et al., 1994).
long-lasting subconductance states (to 5 502.1 6 40.8
ms) were observed following PKA phosphorylation of b-Adrenergic Agonist Response Restored
RyR2 channels in the bilayer (Figure 5B). The phospha- by LVAD Treatment
tase inhibitor okadaic acid (1 mM) increased RyR2 Po Physiologic levels of PKA phosphorylation of RyR2
would increase SR Ca21 release resulting in increasedfrom 0.3 6 0.1 to 0.8 6 0.1 (n 5 5/6, p , 0.001). These
PKA Phosphorylation of RyR2
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Figure 5. PKA Phosphorylation Activates
RyR2 and Induces Subconductance States
(A) Open probability (Po) of a single RyR2
channel plotted as a function of time showing
the effect of MgATP (2 mM) followed by addi-
tion of PKA (2 units).
(B) Single channel tracings corresponding to
the experiment shown in (A). Channel open-
ings are in the upward direction; the current
amplitude for a fully open channel under
these conditions (Ba21 as current carrier) was
z4 pA. Increased Po and multiple subconduc-
tance states are seen after PKA addition. Cor-
responding amplitude histograms are shown
at the right of the tracings for channels before
and after PKA treatment. The subconduc-
tance states have current amplitudes of 1, 2,
or 3 pA, corresponding to 1/4, 1/2, and 3/4
of the full conductance of the channel as
previously described for channels in the ab-
sence of FKBP12 (Brillantes et al., 1994; Marx
et al., 1998). The bottom tracing shows the
characteristic modification of the RyR2 chan-
nels by ryanodine (1 mM). Recordings were
at 0 mV potential across the lipid bilayer
membrane; the dashed lines indicate the
closed state of the channels. Data shown are
representative of four experiments using SR
microsomes containing RyR2 isolated from
two different dogs (two separate isolations
for each animal). Similar results were ob-
tained using RyR2 channels isolated from
normal human heart.
cardiac muscle contractility that explains, at least in increased availability of these RyR2 channels to be
physiologically PKA phosphorylated.part, the inotropic effects of b-adrenergic agonists. The
blunting of the b-adrenergic agonist-induced increase
in cardiac contractility in failing hearts has been attrib- Discussion
uted to the downregulation and desensitization of b-adre-
nergic receptors in failing hearts (Bristow et al., 1992). This study demonstrates that PKA phosphorylation reg-
ulates FKBP12.6 binding to RyR2, providing a mecha-The blunted response to b-adrenergic agonists may
in part be explained by the fact that in failing heart nism for modulating the SR Ca21 release channel re-
quired for EC coupling. PKA hyperphosphorylation ofmuscle, RyR2 channels are already hyperphosphory-
lated (Figures 2A and 2B) and further PKA phosphoryla- RyR2 in failing hearts resulted in the following abnormal
single channel properties: (1) increased Ca21 sensitivitytion of RyR2 cannot occur. Interventions that decrease
PKA phosphorylation of RyR2 back toward the levels for activation and (2) elevated channel activity (Po) asso-
ciated with destabilization of the tetrameric channelobserved in nonfailing hearts should restore b-adrener-
gic-agonist-induced increases in cardiac contractility. complex (manifested as subconductance states includ-
ing long-lasting partially open states never observed inTo test this hypothesis, we used muscle strips isolated
from pre- and post-LVAD hearts placed in organ baths channels from nonfailing hearts). Cosedimentation and
coimmunoprecipitation studies were used to define anunder conditions such that isoproterenol-induced con-
traction could be determined. Compared to normal RyR2 channel macromolecular complex that includes
FKBP12.6, PKA, RII, PP1 and PP2A, and mAKAP, sug-hearts, the pre-LVAD (failing) muscle strips exhibited a
blunted response to isoproterenol (Figure 6C) that was gesting that phosphorylation of the channel is locally
controlled (Figure 7).significantly restored following LVAD treatment. LVAD
treatment restores PKA phosphorylation of RyR2 to nor- FKBP12.6 and FKBP12 are integral components of
the cardiac muscle RyR2 and skeletal muscle RyR1 SRmal levels (Figures 2A and 2B) and reverses the defect
in single channel properties of RyR2/Ca21 release chan- Ca21 release channels, respectively (Jayaraman et al.,
1992; Marks, 1996), required for normal channel gatingnels (data not shown). These data suggest that restora-
tion of sensitivity to b-adrenergic agonists observed in (Brillantes et al., 1994; Kaftan et al., 1996; Marx et al.,
1998). Dissociation of FKBP12/12.6 from RyR1 or RyR2the post-LVAD muscle may be explained in part by the
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Figure 6. Defective RyR2 Channels and Con-
tractility in Failing Heart Muscle
(A) Single channel tracings of RyR2 from: nor-
mal canine heart (top three tracings); failing
canine heart (bottom three tracings). Corre-
sponding amplitude histograms are at right.
The bottom tracing in each set of three shows
the characteristic modification of the RyR2
channels by ryanodine (1 mM). Recordings
were at 0 mV; the dashed lines indicate the
closed state of the channels. Similar results
were obtained using RyR2 channels isolated
from failing human hearts (see text for de-
tails).
(B) RyR2 channels from failing canine hearts
exhibited increased sensitivity to Ca21-
dependent activation compared to channels
from normal hearts, which were generally in-
active at #50 nM free Ca21 in the cis (cyto-
plasmic) chamber (top tracing). RyR2 chan-
nels from failing hearts exhibited two types
of Ca21-dependent activation at #50 nM free
Ca21. Some channels from failing hearts (n 5
15) were active with a low Po (second tracing)
at #50 nM free Ca21, while others (n 5 4)
were extremely active at #50 nM free Ca21,
remaining stably open in a subconductance
state (bottom tracing). Similar results were
obtained using RyR2 channels isolated from
failing human hearts.
(C) Continuous force tracings from human left
ventricular trabeculae during exposure to iso-
proterenol (4 mM). Normal heart sample
showed .3-fold increase in force following
isoproterenol. Muscles from cardiomyopathic
hearts showed either no response in patients
receiving b-agonists prior to transplant or a
blunted response (z2-fold increase) in pa-
tients not receiving b-agonists prior to trans-
plant. Muscle obtained from the apical core
tissue of an LVAD recipient receiving b-ago-
nist prior to surgery showed almost no re-
sponse to isoproterenol. However, muscle
obtained from the same patient after 64 days
of LVAD support shows a .5-fold increase
in response to isoproterenol (n 5 3, p , 0.01).
results in three defects in channel function: (1) subcon- when FKBP12.6 is dissociated from the channel (Figures
5A and 5B). In agreement with our findings, it has beenductance states equal to 1/4, 1/2, and 3/4 of the fully
open channel, (2) increased Po, and (3) increased sensi- reported that PKA phosphorylation of RyR2 increases
the activity of the channel (Hain et al., 1995; Valdivia ettivity to Ca21-dependent activation (Brillantes et al.,
1994; Kaftan et al., 1996; Marx et al., 1998). The in- al., 1995). RyR2 channels isolated from failing hearts
were PKA hyperphosphorylated (Figures 2A and 2B) andcreased Po following removal of FKBP12/12.6 is ex-
plained by the increased sensitivity to Ca21-dependent exhibited the same alterations in function observed in
in vitro PKA phosphorylated channels (Figures 6A andactivation (Brillantes et al., 1994) due to a shift to the
left of the ascending portion of the bell-shaped curve 6B). These data show that PKA hyperphosphorylation
of RyR2 in failing hearts causes a defect in channeldescribing the Ca21 dependence of the RyR channels
(Bezprozvanny et al., 1991). Increased Po at low cytosolic function due to the dissociation of the regulatory subunit
FKBP12.6. Treatment of heart failure with an LVAD thatCa21 (e.g., 50 nM [Ca21]) (see Figure 6B) would result in
inappropriately active SR Ca21 release channels and improves heart function was associated with a decrease
in RyR2 PKA phosphorylation to levels observed in nor-depletion of SR Ca21 that might impair systolic function
of the heart (by diminishing the Ca21 signal that activates mal human hearts (Figures 2A and 2B). In addition, LVAD
treatment resulted in normalized RyR2 single channelmuscle contraction). Inappropriate SR Ca21 release
channel activation at low cytosolic Ca21 might also con- function (i.e., reduction in subconductance states, nor-
malization of the Ca21 sensitivity for activation, and de-tribute to early and delayed afterdepolarizations that
trigger fatal cardiac arrhythmias and cause sudden car- creased Po).
An additional effect of dissociation of FKBP12 fromdiac death (Fozzard, 1992).
Alterations in RyR2 single channel function induced RyR1 is to uncouple gating of neighboring channels
(Marx et al., 1998). We have recently found thatby PKA phosphorylation correspond to those observed
PKA Phosphorylation of RyR2
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Figure 7. Model of the Effects of PKA Phos-
phorylation of RyR2 in the Heart
In the nonfailing heart (left panel) b-agonists
bind to receptors (b1 and b2 adrenergic re-
ceptors, AR) coupled to heterotrimeric G-pro-
teins (Gprot), which in turn activate adenylyl
cyclase (AC), raising cyclic AMP (cAMP) lev-
els and activating PKA. In this model, PKA
phosphorylation of RyR2 induces dissocia-
tion of one FKBP12.6 from the channel, shift-
ing the Ca21 dependence for activation to the
left, increasing the sensitivity of the RyR2 to
activation by Ca21 influx via the voltage-gated
Ca21 channel in the T tubule (dihydropyridine
receptor, DHPR), and increasing RyR2 chan-
nel Po. The result is increased SR Ca21 release
and cardiac contractility. The tetrameric
RyR2 channel is part of a macromolecular
signaling complex that includes four mole-
cules each of RyR2, FKBP12.6, PKA, PP1 and
PP2A, and mAKAP (all components of the
macromolecular complex are shown for only one of the four RyR2 subunits). Ca21 reuptake into the SR occurs via the SR Ca21-ATPase
(SERCA) and its associated regulatory protein phospholamban (PLB).
In failing hearts (right panel), PKA hyperphosphorylation of RyR2 may contribute to the blunted response to b-agonists observed in failing
heart muscle because the channels cannot be further PKA phosphorylated. RyR2 channels in failing hearts exhibit a shift in the Ca21-
dependence for activation such that they are activated at resting levels of cytosolic Ca21.
FKBP12.6 is required for coupled gating between RyR2 hearts compared to channels from normal hearts (Figure
4B). This decrease in FKBP12.6 binding to RyR2 chan-channels (S. O. M. et al., submitted). Coupled gating
provides a mechanism whereby all of the RyR2 channels nels may account for the z70% of RyR2 channels from
failing hearts that exhibited altered single channel prop-in a T tubule/SR junction can be uniformly activated,
resulting in an optimal Ca21 signal to trigger cardiac erties similar to those observed when FKBP12.6 is com-
peted off from the channel using rapamycin or FK506muscle contraction. One consequence of uncoupling
RyR2 channels would be a loss of EC coupling gain, (Brillantes et al., 1994; Kaftan et al., 1996; Marx et al.,
1998). Moreover, 15% of channels from failing heartswhich has been observed experimentally in cardiomyo-
pathic hearts (Gomez et al., 1997). exhibited the most severe defect (long-lasting subcon-
ductance states with Po < 1 at 50 nM cytosolic [Ca21])In the present study, we show that mAKAP, which has
been localized to cardiac SR as well as the perinuclear (e.g., Figure 6B) suggesting that these channels have
,1 FKBP12.6 bound.region (McCartney et al., 1995; Yang et al., 1998), cosedi-
ments and coimmunoprecipitates with RyR2. mAKAP Heart failure is the leading cause of mortality and
morbidity in the United States, accounting for z400,000could bind directly to RyR2, similar to yotia, which binds
directly to the NMDA receptor (Westphal et al., 1999) or deaths annually with z50% of these deaths caused by
disturbances in the cardiac rhythm referred to as suddenvia an adaptor. The PKA regulatory subunit RII binds
directly to AKAPs (Fraser and Scott, 1999) and anchors cardiac death (SCD). A common feature of human heart
failure and of many animal models of heart failure is thatthe PKA catalytic subunit. PP1 and PP2A may interact
with RyR2 directly or via their own regulatory/targeting a hyperadrenergic state and elevated levels of circulat-
ing catecholamines are a marker for increased mortalityproteins, possibly by binding to leucine/isoleucine zip-
pers present in RyR2. in heart failure patients (Cohn et al., 1984).
Downregulation of b-adrenergic receptors in failingb-adrenergic signaling cascade components (the
stimulatory G protein Gs and adenylyl cyclase) have heart muscle and desensitization of these receptors at-
tributable to uncoupling from their downstream signal-been localized to the transverse tubular network in rat
ventricular myocytes (Laflamme and Becker, 1999). ing molecules, G proteins, have been documented (Bris-
tow et al., 1982), yet b-adrenergic blockers have provenThus, one important consequence of anchoring PKA,
RII, PP1, and PP2A to the RyR2 complex and localizing to be one of the most important treatments for heart
failure (CIBIS-II, 1999; MERIT-HF, 1999). cAMP levelsupstream components of the b-adrenergic signaling
cascade to the T tubule±SR junction, is that phosphory- and PKA activity were unchanged in failing human hearts
(Regitz-Zagrosek et al., 1994; Kirchhefer et al., 1999) orlation/dephosphorylation of RyR2 can be regulated lo-
cally at the site of EC coupling. The stoichiometry of cAMP levels were reduced but PKA activity unchanged
(Bohm et al., 1994). b-adrenergic blockade has beenPKA back-phosphorylation for the channels from failing
hearts was 0.7 (compared to 3.8 for fully dephosphory- viewed as counterintuitive in heart failure therapy since
the adrenergic system may be downregulated and nega-lated channels and 3.1 for RyR2 from nonfailing hearts),
indicating that approximately 3±4 PKA sites on RyR2 tive inotropic drugs are considered potentially danger-
ous to patients. Therefore, a mechanistic understandingwere phosphorylated in failing hearts compared to ,1
on RyR2 from nonfailing hearts. RyR2 PKA hyperphos- of the molecular basis for the therapeutic benefit af-
forded by b-adrenergic blockers in heart failure wouldphorylation explains the z60% decrease in the amount
of FKBP12.6 bound to the RyR2 channels from failing be an important advance.
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RyR2 was initiated with PKA (5 units) and MgATP (33 mM) andIn the present study, we show that the SR Ca21 release
terminated after incubation for 5 min at RT with 5 ml of stop solutionchannel RyR2 is unexpectedly PKA hyperphosphory-
(4% SDS and 0.25 M DTT). For RyR2 phosphorylation with PKC (0.05lated in failing hearts. These data raise the concept that
units, Calbiochem), 1.5 mM CaCl2 was added, and for phosporylationlocal signaling may increase rather than decrease phos- with CaMKII (0.2 mg, Upstate Biotech, Lake Placid, NY), 1.5 mM
phorylation of PKA substrates in cardiomyocytes from CaCl2 and 5 mM calmodulin were added. In some experiments, the
ATP contained 10% [g32P]ATP (NEN Life Sciences, Boston, MA).failing hearts.
Samples were heated to 958C, size-fractionated on 6% SDS-PAGE,One explanation for the surprising finding of PKA hy-
and RyR2 radioactivity was quantified using a Molecular Dynamicsperphosphorylation of RyR2 is that targeting of phos-
Phosphorimager and ImageQuant software (Amersham Pharmaciaphatases to RyR2 may be downregulated in failing
Biotech, Piscataway, NJ). Nonspecific phosphorylation (not inhib-
hearts. Indeed, we found that the levels of PP1 and PP2A ited by PKA inhibitor) was subtracted, the resulting value was di-
associated with RyR2 were significantly decreased in vided by the amount of RyR2 protein (determined by immunoblotting
and densitometry or [3H] ryanodine binding) and expressed as thefailing hearts (Figures 2C and 2D). Cellular PP1 levels
inverse of the PKA-dependent [g32P]ATP signal. Microcystin-Sepha-are increased in failing hearts (Neumann et al., 1997);
rose (35 ml, UBI) was used to isolate RyR2 from 200 mg of cardiacthus, the decrease in RyR2-associated PP1 must be due
SR by incubating at 48C for 1 hr followed by washing. Beads wereto a specific decrease in PP1 association with RyR2 that
resuspended in 63 SDS loading buffer and boiled, and the superna-
cannot be explained by a generalized decrease in PP1 tant was size-fractionated on SDS-PAGE. PP1 and PP2A bound
levels in the heart. to the microcystin-Sepharose beads were competed off with free
microcystin-LR (Calbiochem). Maximum PKA-dependent phosphor-Defects in Ca21 regulation that could explain the de-
ylation was determined using RyR2 pretreated with alkaline phos-creased contractility observed in failing hearts, including
phatase (AP, 1:100 enzyme:protein, New England Biolabs) for 20a reduced amplitude and slowed decay of the Ca21 tran-
min at 378C. The stoichiometry of RyR2 PKA phosphorylation wassient, have been described (Morgan et al., 1990; Beuck-
determined using [g32P]ATP standards. The 32P/RyR2 ratio was cal-
elmann et al., 1992). The release and reuptake of Ca21 culated by dividing 32P-phosphorylation by the amount of high-affin-
from the SR controls the force of contraction during ity [3H]ryanodine binding (one high-affinity ryanodine binding site
per RyR2).systole in the heart. SR Ca21 release occurs via activa-
tion of RyR2, and Ca21 reuptake occurs via the SR Ca21-
ImmunoblotsATPase which in turn is regulated by phospholamban.
Immunoblots were performed as described (Moschella and Marks,PKA has multiple substrates in cardiomyocytes includ-
1993) using: anti-FKBP12 (1:1000), anti-RyR (5029, 1:3000) (Jayara-ing phospholamban, the L-type Ca21 channel on the
man et al., 1992), anti-PP1 (1:1000), anti-PP2A (1:1000), anti-CnA
sarcolemma and components of the contractile appara- (1:1000), anti-PKA catalytic subunit (1:1000, Transduction Labs, Lex-
tus. It has been appreciated for some time that b-adren- ington, KY), anti-phosphoserine (1 mg/ml, Zymed San Francisco,
CA), and anti-mAKAP (VO56) (Kapiloff et al., 1999). After washing,ergic agonists can modulate the activity of molecules
membranes were incubated with peroxidase-conjugated goat anti-involved in regulating cardiac contractility. Clearly, a
rabbit or goat anti-mouse IgG antiserum (1:3000, Boehringer-Mann-disease as complex as heart failure involves an interplay
heim) for 60 min at RT, washed three times with TBS and 0.1%between a number of molecules and signaling pathways
Tween 20, and developed using enhanced chemiluminescence
that contribute to the regulation of Ca21 homeostasis. (ECL, Amersham).
One key point distinguishing the present study is the
identification of a functional defect in a Ca21 handling Yeast Two-Hybrid Assay to Identify the FKBP12.6 Binding Site
Human FKBP12.6 cDNA was cloned into the yeast two-hybrid vec-molecule that occurs not only in animal models (e.g.,
tor pEG202 (OriGene Technologies, Rockville, MD) to makethe paced dog model) but also in human failing hearts
pEGFKBP12.6 (FKBP12.6 fused to the GAL4 DNA binding domain);and is reversed by treatment of the heart failure (e.g.,
human RyR2 cDNA fragments cloned into pJG4±5 (OriGene) werewith an LVAD) in humans.
confirmed by sequencing. The yeast two-hybrid assay was per-
The present study provides a novel mechanism for formed using the DupLEX-A yeast system (OriGene). pEGFKBP12.6
modulating RyR2 channel function by physiologically and pAD-GAL4RyR2/2361±2496 were cotransformed into the rapa-
mycin resistant mutant yeast strain Y663 (Lorenz and Heitman, 1995)controlling the binding of FKBP12.6 to the channel via
and liquid b-galactosidase assays were performed in the absencePKA phosphorylation. Furthermore, the finding of PKA
or presence of rapamycin (0.1, 1.0, and 10 mM) which competeshyperphosphorylated channels with defective function
with RyR2 for binding to FKBP12.6.in failing hearts provides a mechanism for cardiac dys-
function in heart failure.
Site-Directed Mutagenesis and In Vitro Mapping
pGST-RyR2 constructs were generated using rabbit or human RyR2
cDNA, and fusion proteins were expressed and purified with gluta-Experimental Procedures
thione Sepharose beads. Site-directed mutagenesis was performed
using the 59-39 site-directed mutagenesis kit (Amersham PharmaciaImmunoprecipitation and Back-Phosphorylation of RyR2
Biotech). pGST-RyR2 fusion proteins bound to Sepharose beadsCardiac SR (200 mg) or homogenates (500 mg), prepared from ven-
were incubated with canine cardiac SR (200 mg), pelleted, washedtricular tissue as described (Kaftan et al., 1996), were suspended in
with modified RIPA buffer, size-fractionated on SDS-PAGE, and0.5 ml of buffer (50 mM Tris-HCl [pH 7.4], 0.9% NaCl, 0.5 mM NaF,
immunoblotted with the indicated antibodies.0.5 mM Na3VO4, 0.25% Triton X100, and protease inhibitors) and
incubated with the indicated antibody O/N at 48C (IgG alone was
used as a negative control for each antibody, data not shown). Immunohistochemistry
Human cardiac tissue was fixed in 10% neutral buffered formalinProtein A Sepharose beads were added, incubated at 48C for 1 hr,
washed with 13 phosphorylation buffer (8 mM MgCl, 10 mM EGTA, and embedded in paraffin. Sections (4 mM) were dried O/N at 378C,
dewaxed, rehydrated, incubated with PBS 1 0.2% Tween-20 for 550 mM Tris/piperazine-N,N9-bis[2-ethanesulfonic acid] [pH 6.8]), and
resuspended in 10 ml of 1.53 phosphorylation buffer containing min, then incubated with 5% goat serum in PBS for 1 hr at RT.
Sections were then incubated with preimmune rabbit serum (IgG)either vehicle alone, PKA catalytic subunit (Sigma, St. Louis, MO),
PKA plus PKA inhibitor (PKI5±24, 500 nM, Calbiochem, San Diego, CA), or primary antibody [mAKAP (VO56), RyR2 (monoclonal, Affinity Bio-
reagents); 1:50] in PBS 1 3% BSA O/N at 48C, washed in PBS, thenor cAMP as indicated. Back-phosphorylation of immunoprecipitated
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incubated with either FITC or rhodamine secondary antibody (1:100; phospholamban in non-failing and failing myocardium. Cardiovasc.
Res. 28, 1713±1719.Zymed) for 1 hr at RT, washed with PBS, stained with Hoechst dye
(10 mg/ml) for 5 min, and washed with PBS. For double immunostain- Brillantes, A.B., Ondrias, K., Scott, A., Kobrinsky, E., Ondriasova,
ing, slides were sequentially stained with 2 individual 18 antibodies E., Moschella, M.C., Jayaraman, T., Landers, M., Ehrlich, B.E., and
followed by simultaneous incubation with 28 antibodies. Slides were Marks, A.R. (1994). Stabilization of calcium release channel (ryanod-
examined using a Nikon microscope (1003 objective) and images ine receptor) function by FK506-binding protein. Cell 77, 513±523.
were acquired with a SPOT RT camera (Diagnostic Instruments Inc) Bristow, M.R., Ginsburg, R., Minobe, W., Cubicciotti, R.S., Sageman,
using Adobe Photoshop. W.S., Lurie, K., Billingham, M.E., Harrison, D.C., and Stinson, E.B.
(1982). Decreased catecholamine sensitivity and beta-adrenergic-
Single Channel Recordings receptor density in failing human hearts. N. Engl. J. Med. 307,
Single channel recordings of RyR2 were performed and analyzed 205±211.
as described (Brillantes et al., 1994). At the conclusion of each
Bristow, M.R., Minobe, W., Rasmussen, R., Larrabee, P., Skerl, L.,experiment, ryanodine and/or ruthenium red were applied to confirm
Klein, J.W., Anderson, F.L., Murray, J., Mestroni, L., Karwande, S.V.,the identity of channels as ryanodine receptors. Results are pre-
et al. (1992). Beta-adrenergic neuroeffector abnormalities in the fail-sented as mean 6 standard deviation; the Student's t test was used
ing human heart are produced by local rather than systemic mecha-for statistical analyses.
nisms. J. Clin. Invest. 89, 803±815.
Cameron, A.M., Nucifora, F.C., Jr., Fung, E.T., Livingston, D.J., Al-Human Heart Samples
dape, R.A., Ross, C.A., and Snyder, S.H. (1997). FKBP12 binds theThe use of human tissues was approved by the Institutional Review
inositol 1,4,5-trisphosphate receptor at leucine- proline (1400±1401)Board of Columbia-Presbyterian Medical Center. Normal and failing
and anchors calcineurin to this FK506-like domain. J. Biol. Chem.human heart tissues were obtained as previously described from
272, 27582±27588.patients undergoing cardiac transplant (Go et al., 1995). LVADs
(Thermo Cardiosystems Inc., Woburn, MA) were implanted in pa- Chen, Y.G., Liu, F., and Massague, J. (1997). Mechanism of TGFbeta
tients as a bridge to heart transplantation according to standard receptor inhibition by FKBP12. EMBO J. 16, 3866±3876.
clinical practice (Frazier, 1994). CIBIS-II (1999). The cardiac insufficiency bisoprolol study II (CIBIS-
II): a randomised trial. Lancet 353, 9±13.
Muscle Strip Function
Cohn, J.N., Levine, T.B., Olivari, M.T., Garberg, V., Lura, D., Francis,
Trabeculae (diameters ,1 mm, lengths .3 mm) from human left
G.S., Simon, A.B., and Rector, T. (1984). Plasma norepinephrine as
ventricular apical core samples obtained at the time of LVAD implan-
a guide to prognosis in patients with chronic congestive heart failure.
tation or from hearts explanted at the time of orthotopic cardiac
N. Engl. J. Med. 311, 819±823.
transplantation were placed in a standard muscle bath, attached to
Fozzard, H.A. (1992). Afterdepolarizations and triggered activity. Ba-a force transducer, stimulated at 1 Hz, and left to equilibrate for 1
sic Res. Cardiol. 87, 105±113.hr prior to study at slack length, then stretched progressively to the
Fraser, I.D., and Scott, J.D. (1999). Modulation of ion channels: apoint of maximal tension development (Lmax). b-adrenergic response
ªcurrentº view of AKAPs. Neuron 23, 423±426.was tested by superfusing the muscle with Krebs-Ringer solution
containing isoproterenol (4 mM). Frazier, O.H. (1994). First use of an untethered, vented electric left
ventricular assist device for long-term support. Circulation 89, 2908±
Canine Heart Failure Model 2914.
Canine heart failure was induced by rapid cardiac pacing as de- Go, L.O., Moschella, M.C., Watras, J., Handa, K.K., Fyfe, B.S., and
scribed previously (Wang et al., 1997). Severe heart failure was Marks, A.R. (1995). Differential regulation of two types of intracellular
evidenced by an z40% reduction in LV dP/dtmax (to z1800 mm Hg/s), calcium release channels during end-stage heart failure. J. Clin.
20% reductions in peak LV and mean aortic pressure (to 100 and Invest. 95, 888±894.
85 mm Hg, respectively), 50% increase in resting heart rate (to 132
Gomez, A.M., Valdivia, H.H., Cheng, H., Lederer, M.R., Santana, L.beats/min), and a rise in end-diastolic pressure to .20 mm Hg
F., Cannell, M.B., McCune, S.A., Altschuld, R.A., and Lederer, W.J.(Wang et al., 1997). All procedures were approved by the Institutional
(1997). Defective excitation-contraction coupling in experimentalAnimal Care Committee.
cardiac hypertrophy and heart failure. Science 276, 800±806.
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